Age-dependent impairment of number and angiogenic potential of adipose tissue-derived progenitor cells

Madonna, Rosalinda; Renna, Francesca Vera; Cellini, Carlo; Cotellese, Roberto; Picardi, N; Francomano, F; Innocenti, Paolo; Caterina, Raffaele De

doi:10.1111/j.1365-2362.2010.02384.x

Cited by 89 publications

(64 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While an analysis of breast tissues specimens from >180 women donors aged 16-73 did not observe an age dependent difference in stromal cell numbers or adipogenesis, increased body mass index correlated significantly with reduce cell numbers and differentiation [9]. Clinical studies examining subcutaneous adipose tissue from 12 to 52 donors have reported reduced ASC adipogenesis, angiogenesis, osteogenesis, and/or proliferative capacity as a function of advancing donor age [10][11][12]. Similarly, a detailed comparison of five different subcutaneous depots determined that ASC isolated from the arm and thigh best maintained adipogenic potential as a function of advancing age [12].…”

Section: Donor Considerationsmentioning

confidence: 99%

Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation

et al. 2011

View full text Add to dashboard Cite

Subcutaneous fat has emerged as an alternative tissue source for stromal/stem cells in regenerative medicine. Over the past decade, international research efforts have established a wealth of basic science and preclinical evidence regarding the differentiation potential and regenerative properties of both freshly processed, heterogeneous stromal vascular fraction cells and culture expanded, relatively homogeneous adipose-derived stromal/stem cells. The stage has been set for clinicians to translate adipose-derived cells from the bench to the bedside; however, this process will involve “development” steps that fall outside of traditional “hypothesis-driven, mechanism-based” paradigm. This concise review examines the next stages of the development process for therapeutic applications of adipose-derived cells and highlights the current state of the art regarding clinical trials. It is recommended that the experiments addressing these issues be reported comprehensively in the peer-review literature. This transparency will accelerate the standardization and reproducibility of adipose-derived cell therapies with respect to their efficacy and safety.

show abstract

Section: Donor Considerationsmentioning

confidence: 99%

Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Most of the data regarding ADSC regenerative potential were obtained from cells delivered from relatively healthy young donors; however, it was known that aging and disease itself may negatively affect MSC activities [21][22][23][24][25][26], including proliferation and differentiation potential [27][28][29][30] as well as angiogenic properties [29,31]. Because MSCs are considered to be components of the vessel wall and take part in its reparation after injury, their cellular modification due to aging can be an important pathogenic factor of agerelated diseases such as atherosclerosis, diabetes, and arterial hypertension [32].…”

Section: Introductionmentioning

confidence: 99%

Adipose-Derived Mesenchymal Stromal Cells From Aged Patients With Coronary Artery Disease Keep Mesenchymal Stromal Cell Properties but Exhibit Characteristics of Aging and Have Impaired Angiogenic Potential

Efimenko

Dzhoyashvili

et al. 2013

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Tissue regeneration is impaired in aged individuals. Adipose-derived mesenchymal stromal cells (ADSCs), a promising source for cell therapy, were shown to secrete various angiogenic factors and improve vascularization of ischemic tissues. We analyzed how patient age affected the angiogenic properties of ADSCs. ADSCs were isolated from subcutaneous fat tissue of patients with coronary artery disease (CAD; n = 64, 43-77 years old) and without CAD (n = 31, 2-82 years old). ADSC phenotype characterized by flow cytometry was CD90 + /CD73 + /CD105 + /CD45 2 /CD31 2 for all samples, and these cells were capable of adipogenic and osteogenic differentiation. ADSCs from aged patients had shorter telomeres (quantitative reverse transcription polymerase chain reaction) and a tendency to attenuated telomerase activity. ADSC-conditioned media (ADSC-CM) stimulated capillary-like tube formation by endothelial cells (EA.hy926), and this effect significantly decreased with the age of patients both with and without CAD. Angiogenic factors (vascular endothelial growth factor, placental growth factor, hepatocyte growth factor, angiopoetin-1, and angiogenin) in ADSC-CM measured by enzyme-linked immunosorbent assay significantly decreased with patient age, whereas levels of antiangiogenic factors thrombospondin-1 and endostatin did not. Expression of angiogenic factors in ADSCs did not change with patient age (real-time polymerase chain reaction); however, gene expression of factors related to extracellular proteolysis (urokinase and its receptor, plasminogen activator inhibitor-1) and urokinase-type plasminogen activator receptor surface expression increased in ADSCs from aged patients with CAD. ADSCs from aged patients both with and without CAD acquire aging characteristics, and their angiogenic potential declines because of decreasing proangiogenic factor secretion. This could restrict the effectiveness of autologous cell therapy with ADSCs in aged patients. STEM CELLS TRANSLATIONAL MEDICINE 2014;3:32-41

show abstract

“…Adult human EPDCs were found to reduce remodelling and increase ejection fraction when transplanted into an immunodeficient mouse model of myocardial infarction [101]. Moreover, Smart et al reported that the activation of quiescent EPDCs in the adult mouse heart can be enhanced using a naturally occurring protein called thymosin beta 4 (Tβ4; a small actin-binding protein that activates integrin-linked kinase).…”

Section: Epicardium-derived Stem Cellsmentioning

confidence: 99%

Endogenous Cardiac Stem Cell Therapy for Ischemic Heart Failure

Hsiao

Carr²

2013

J Clin Exp Cardiolog

View full text Add to dashboard Cite

Cardiovascular disease remains the number one cause of morbidity and mortality in the world. With great advances in medical and interventional therapies, patients who suffer from acute myocardial infarction have a longer life expectancy than before, but gradually develop chronic heart failure in their later life due to irreversible loss of cardiomyocytes. So far, heart transplantation is the only therapeutic option for advanced heart failure. However, the shortage of donor organs largely limits its role as the gold standard therapy. In the past decades, stem cell-based regenerative medicine has been proposed as a promising approach for the treatment of heart failure based on numerous animal studies. A variety of potential stem cell types, including skeletal myoblasts and bone marrowderived stem cells, have been investigated in clinical trials for cardiac repair and regeneration, but have shown mixed results in heart functional improvement or life-threatening disadvantages such as ventricular arrhythmia. On the other hand, due to the advantages of autologous origin and cardiac-committed lineage, cardiac stem cell therapy has emerged as a promising cell-based strategy for treatment of HF. Thus, this review discusses the current therapies for heart failure and further focuses on stem cell therapy using different endogenous cardiac stem cells, purified by stem cell surface markers (e.g., c-kit or Sca-1) or derived from explants via the formation of cardiospheres. In addition, the potential effect of patient age on cell-based therapy for heart disease is discussed.

show abstract

Age-dependent impairment of number and angiogenic potential of adipose tissue-derived progenitor cells

Abstract: Ageing may alter the availability of adipose tissue-derived CD45(-)/CD34(+)/CD133(+) cells and their angiogenic functional capacity. Such changes may impair the use of adipose tissue as source of autologous PCs in elderly patients.

Cited by 89 publications

References 34 publications

Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation

Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation

Adipose-Derived Mesenchymal Stromal Cells From Aged Patients With Coronary Artery Disease Keep Mesenchymal Stromal Cell Properties but Exhibit Characteristics of Aging and Have Impaired Angiogenic Potential

Endogenous Cardiac Stem Cell Therapy for Ischemic Heart Failure

Contact Info

Product

Resources

About